Email: cspc@cspc.cn
News
October 13, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - JSKN003 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED COLORECTAL
Next: VOLUNTARY ANNOUNCEMENT - SYH2070 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
